Revolutionizing the Treatment of Heart Failure with First-in-class Structural Heart Devices

Corvia Medical, Inc., previously DC Devices, Inc., is dedicated to revolutionizing the treatment of heart failure with first-in-class structural heart devices. The company has developed the world’s first transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). The InterAtrial Shunt Device (IASD), also known as the Corvia™ Atrial Decompression System, is the world’s first transcatheter device approved in the European Union to treat HFpEF. By facilitating continuous and dynamic decompression of the left atrium, the IASD aims to improve heart failure symptoms and quality of life, decrease heart failure hospitalization rates, and reduce the overall cost burden of managing heart failure patients.

Year Invested: 2009
Location: Tewksbury, Mass.

Recent News

November 16, 2016
Corvia Medical Announces Strong Positive One-Year Data from Reduce LAP-HF Clinical Study

March 7, 2016
Corvia Medical Receives IDE Approval for REDUCE LAP-HF I Clinical Study & Announces Agreement with Strategic Partner for Exclusive Option to Purchase Company

June 22, 2015
DC Devices Completes Enrollment In Clinical Trial of the First Transcatheter Device to Treat Diastolic Heart Failure; Announces Name Change to Corvia Medical

Read More News

Associated Team Members

Mark Levin